2.8.7 Chemotherapy

Introduction

Chemotherapy in the USMLE context refers to pharmacologic treatment of cancer and of some noncancer proliferative or immune conditions. For Step 1 you mainly need to recognize drug classes, core mechanisms, major toxicities, and a few key clinical uses. Detailed protocols, regimens, and drug combinations belong more to clinical training and are not the focus here. Instead, this chapter introduces how chemotherapeutic drugs work at the cellular level and highlights the classic, repeatedly tested agents.

General Principles of Chemotherapy

Chemotherapy targets rapidly dividing cells by interfering with DNA synthesis, DNA integrity, or mitosis. Cancer cells divide faster and with less control than most normal cells, which makes them relatively more sensitive. However, normal tissues with high turnover, such as bone marrow, gastrointestinal epithelium, hair follicles, and gonads, are also vulnerable. This concept explains much of the toxicity pattern that appears in questions.

Many antineoplastic drugs are cell cycle specific, meaning they act at a particular phase like S phase or M phase. Others are cell cycle nonspecific and can damage cells in many phases. On exams you are often asked to match drugs to phases, especially for microtubule inhibitors and antimetabolites.

Chemotherapy is often given in cycles to allow normal tissues to recover, to reach cells in different phases, and to limit cumulative toxicity. Combination regimens frequently include drugs with different mechanisms and nonoverlapping toxicities, which increases tumor kill while trying to preserve tolerability.

Classification by Mechanism

A useful way for USMLE preparation is to classify chemotherapy drugs by how they damage or block DNA or its associated processes. The major mechanistic groups are antimetabolites, alkylating agents, microtubule inhibitors, topoisomerase inhibitors, antitumor antibiotics, hormonal agents, targeted therapies, and miscellaneous drugs such as platinum compounds and proteasome inhibitors.

The table below summarizes some of the most testable mechanisms and associated toxicities. The details of specific drugs will be developed in the following sections.

Cell Cycle Specific vs Nonspecific Agents

Some questions explicitly ask whether a drug is cell cycle specific or not. The distinction is based on which phase of the cell cycle is targeted. Since the full cell cycle is covered in basic cell biology, here we focus on the association of the main chemotherapy classes with phases.

S phase specific drugs interfere with DNA synthesis. These include most antimetabolites and some topoisomerase inhibitors. You should associate S phase with nucleotide analogs such as cytarabine and 5 fluorouracil and with drugs like methotrexate that block folate metabolism.

M phase specific drugs disrupt the mitotic spindle. These are the microtubule inhibitors, especially the vinca alkaloids and taxanes. Neurotoxicity and peripheral neuropathy are common clues in questions involving these agents.

Cell cycle nonspecific drugs such as many alkylating agents and anthracyclines can act in multiple phases, sometimes including resting cells. These drugs are particularly useful for bulky, rapidly growing tumors but are also more damaging to normal tissues.

Antimetabolites

Antimetabolites structurally resemble natural metabolites such as folate, purines, or pyrimidines. They compete with or block the normal building blocks of DNA and RNA. Their activity peaks in S phase since that is when DNA is synthesized.

Folate antagonists such as methotrexate inhibit dihydrofolate reductase. This decreases tetrahydrofolate, which is necessary for synthesis of thymidine and purine nucleotides. Clinically, this leads to impaired DNA replication in rapidly dividing cells. On exams methotrexate is linked to myelosuppression, mucositis, hepatotoxicity, and teratogenicity. Folinic acid rescue with leucovorin can reduce some toxic effects on normal cells.

Pyrimidine analogs such as 5 fluorouracil and cytarabine interfere with pyrimidine metabolism. 5 fluorouracil forms a complex that inhibits thymidylate synthase and leads to thymidine deficiency. Cytarabine is a cytidine analog that inhibits DNA polymerase. Both drugs produce significant bone marrow suppression, and 5 fluorouracil is also associated with photosensitivity and hand foot syndrome.

Purine analogs such as 6 mercaptopurine and its relatives interfere with purine synthesis or metabolism. Many are activated by enzymes such as hypoxanthine guanine phosphoribosyltransferase. This feature leads to interactions with xanthine oxidase inhibitors such as allopurinol, because catabolism of the drug is reduced, and toxicity increases.

A recurring exam theme is the parallel between antimetabolites used for cancer and similar agents used for autoimmune diseases. Methotrexate serves as a prime example, used both for malignancies and at lower doses for conditions such as rheumatoid arthritis.

Alkylating Agents

Alkylating agents covalently attach alkyl groups to DNA bases. This can result in crosslinking between DNA strands or within a strand and in mispairing during replication. The general result is impaired replication and transcription and eventually apoptosis. These drugs are often cell cycle nonspecific and are particularly effective for rapidly proliferating tumors.

Nitrogen mustards such as cyclophosphamide and ifosfamide are classic exam drugs. They require activation by hepatic cytochrome P450 enzymes. A characteristic toxicity is hemorrhagic cystitis caused by the metabolite acrolein. The protective agent mesna binds acrolein and reduces this bladder toxicity. Other toxicities include myelosuppression and risk of secondary malignancies such as leukemia.

Nitrosoureas such as carmustine are notable for crossing the blood brain barrier. They are used for brain tumors and thus are tested in questions that combine central nervous system tumors with an alkylating mechanism. Pulmonary toxicity and CNS effects can occur.

A key theme with alkylating agents is their potential to cause secondary cancers years after treatment. This risk is related to their mutagenic effects on normal hematopoietic cells.

Platinum Compounds

Platinum compounds such as cisplatin and carboplatin form DNA crosslinks through platinum DNA adducts. Although structurally distinct from classic alkylating agents, they behave similarly at the DNA level and are often grouped with alkylators for exam purposes.

Cisplatin is strongly associated with nephrotoxicity, ototoxicity, and peripheral neuropathy. Questions often mention high frequency hearing loss and kidney damage after treatment for testicular or ovarian cancer. Adequate hydration and use of protective agents such as amifostine can reduce nephrotoxicity.

Carboplatin has less nephrotoxicity and ototoxicity than cisplatin, but more myelosuppression. Recognizing this trade off in toxicity profiles is useful for drug selection questions.

Microtubule Inhibitors

Microtubule inhibitors interfere with the assembly or disassembly of microtubules, which are essential for mitotic spindle function. These agents are M phase specific and primarily affect rapidly dividing cells during mitosis. They also impact microtubules in neurons, which helps explain their neurotoxicity.

Vinca alkaloids such as vincristine and vinblastine inhibit microtubule polymerization. Vincristine is especially associated with peripheral neuropathy, areflexia, and paralytic ileus because of autonomic nerve damage. It tends to cause less bone marrow suppression compared with vinblastine. Vinblastine is often remembered for more pronounced myelosuppression.

Taxanes such as paclitaxel stabilize microtubules and prevent their depolymerization. This also blocks cell division in M phase but by opposing the dynamic nature of spindle fibers. Paclitaxel is associated with myelosuppression, peripheral neuropathy, and hypersensitivity reactions that may be related to its solvent.

The shared theme is disruption of microtubule dynamics and a clinical pattern of neuropathy and alopecia. Distinguishing between prevented polymerization as with vinca alkaloids and prevented depolymerization as with taxanes is commonly tested.

Topoisomerase Inhibitors

Topoisomerases are enzymes that control the topologic state of DNA during replication and transcription. They create temporary breaks in DNA strands to relieve supercoiling. Inhibiting these enzymes leads to DNA damage and apoptosis.

Topoisomerase II inhibitors such as etoposide and teniposide inhibit the re ligation step of the topoisomerase II enzyme. This causes double strand DNA breaks and cellular death. These drugs are associated with myelosuppression and alopecia and can increase the risk of secondary leukemia due to damage to hematopoietic stem cells.

Topoisomerase I inhibitors such as irinotecan and topotecan target the topoisomerase I enzyme, which normally produces single strand breaks to relieve torsional strain. Their inhibition results in persistent single strand breaks that convert into double strand breaks during replication. A characteristic toxicity of irinotecan is severe diarrhea, often delayed, along with myelosuppression.

For exam purposes it is important to match topoisomerase I with the camptothecin derivatives and topoisomerase II with the podophyllotoxins such as etoposide. This mapping is frequently tested in mechanism based questions.

Antitumor Antibiotics

Antitumor antibiotics are microbial products that interfere with DNA. They should not be confused with standard antibiotics used for infections, although some originally came from similar sources.

Anthracyclines such as doxorubicin and daunorubicin intercalate into DNA, generate free radicals, and inhibit topoisomerase II. This combination damages DNA and cell membranes. Their most feared toxicity is dose dependent cardiomyopathy, which can lead to congestive heart failure. The iron chelator dexrazoxane can be used to reduce this cardiotoxicity. Other common toxicities are myelosuppression and alopecia.

Bleomycin is a glycopeptide that induces free radical formation and causes single and double strand DNA breaks. It is unique among many cytotoxic drugs because it causes minimal myelosuppression. Instead, its dose limiting toxicity is pulmonary fibrosis, along with skin changes. For Step 1 you should associate bleomycin with lung toxicity and recall that it is often used in testicular cancer regimens.

The pattern to remember is that anthracyclines damage the heart while bleomycin primarily damages the lungs. Both are linked to free radical generation but affect different organs as their main limiting toxicity.

Hormonal and Endocrine Therapies

Some tumors depend on hormones for growth. Hormonal therapies exploit this dependence by blocking hormone receptors or inhibiting hormone synthesis. They are particularly important for breast and prostate cancers and are a frequent topic in USMLE style questions.

Selective estrogen receptor modulators such as tamoxifen act as antagonists on estrogen receptors in breast tissue but as partial agonists in endometrium and bone. This explains their use in estrogen receptor positive breast cancer and their increased risk of endometrial carcinoma and venous thromboembolism. Raloxifene shares some properties but acts differently in endometrium and is mainly used for osteoporosis prevention.

Aromatase inhibitors such as anastrozole reduce estrogen synthesis by blocking the conversion of androgens to estrogens. They are used in postmenopausal women with estrogen receptor positive breast cancer and are associated with osteoporosis and arthralgias.

For prostate cancer, androgen deprivation is central. GnRH agonists like leuprolide, when given continuously, suppress luteinizing hormone and follicle stimulating hormone and reduce testosterone production. Antiandrogens such as flutamide block androgen receptors. Combined, these treatments reduce the growth stimulus in prostate cancer but can cause hot flashes, impotence, and gynecomastia.

The key is to identify whether a cancer is hormone sensitive and then to select the appropriate hormone pathway to block, either at the receptor or at the level of synthesis.

Targeted Therapies

Targeted therapies focus on specific molecular abnormalities such as mutated kinases, overexpressed receptors, or unique tumor antigens. They are more selective than traditional chemotherapy, but they still have important toxicities that are frequently tested.

Tyrosine kinase inhibitors such as imatinib target specific kinases. Imatinib inhibits BCR ABL, the fusion protein produced by the Philadelphia chromosome translocation in chronic myelogenous leukemia, and also inhibits c KIT in gastrointestinal stromal tumors. Common adverse effects include fluid retention, edema, and myelosuppression.

Epidermal growth factor receptor inhibitors such as erlotinib inhibit the tyrosine kinase activity of the EGFR. They are used mainly for certain non small cell lung cancers with EGFR mutations. Typical side effects include a papulopustular skin rash and diarrhea. The presence of a characteristic acneiform rash is sometimes a marker of response.

Monoclonal antibodies such as trastuzumab target cell surface proteins. Trastuzumab binds HER2, a receptor tyrosine kinase overexpressed in some breast cancers, and triggers antibody dependent cell mediated cytotoxicity. Its major toxicity is cardiomyopathy, which can be reversible. Rituximab targets CD20 on B cells and is used in several B cell malignancies and autoimmune conditions. It can cause infusion reactions and increase the risk of infections including reactivation of hepatitis B.

The unifying idea is that targeted therapies require knowing the tumor’s molecular profile, such as HER2 or BCR ABL status. USMLE questions often embed this information and then ask which drug would be appropriate.

Miscellaneous Cytotoxic Agents

A few cytotoxic agents do not fit neatly into the major categories but are common enough to appear on exams. Knowing one or two key facts about each is often sufficient.

Hydroxyurea inhibits ribonucleotide reductase, which reduces the conversion of ribonucleotides to deoxyribonucleotides. This decreases DNA synthesis and arrests cells in S phase. It is used in some leukemias and for sickle cell disease, where it increases fetal hemoglobin levels. Its main toxicity is myelosuppression.

Asparaginase and its pegylated forms deplete extracellular asparagine by converting it to aspartic acid and ammonia. Some acute lymphoblastic leukemias are unable to synthesize asparagine and depend on external sources, so they are sensitive to this drug. Hypersensitivity reactions, pancreatitis, and coagulopathy are notable adverse effects.

Bortezomib is a proteasome inhibitor that blocks the degradation of proapoptotic factors. This can lead to apoptosis of malignant plasma cells, which is useful in multiple myeloma. Neuropathy and myelosuppression are common toxicities.

Each of these agents targets a distinct metabolic or protein pathway rather than classic DNA structure or microtubules, and they often appear in questions as part of specialized regimens for hematologic malignancies.

Common Toxicities and Their Management

Many exam questions test recognition of characteristic toxicities for specific drugs alongside strategies to prevent or treat them. It is helpful to link certain drugs with unique protective measures.

Cyclophosphamide induced hemorrhagic cystitis can be prevented with mesna, which binds the toxic metabolite in urine. Anthracycline induced cardiomyopathy risk is reduced with dexrazoxane, which chelates iron and limits free radical formation in cardiac tissue. Cisplatin nephrotoxicity can be mitigated with adequate hydration and sometimes amifostine. Methotrexate toxicity can be lessened with leucovorin, also called folinic acid, which bypasses dihydrofolate reductase.

Toxicities such as myelosuppression are often managed with dose adjustments, growth factors like granulocyte colony stimulating factor, or transfusion support. Recognizing that most traditional antineoplastic agents suppress bone marrow aids in understanding neutropenic fever, infection risk, and anemia in cancer patients.

Understanding these characteristic patterns and supportive strategies is central for USMLE style questions that ask not only which drug was used, but how to manage or prevent its adverse effects.